|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
 |
Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasisCorless JA, Warburton CJ
Bookmark this:
     more ...
SummaryLeukotriene receptor antagonists for non-cystic fibrosis bronchiectasisLeukotriene receptor antagonists are a new class of drug which may have an anti-inflammatory action in some patients with asthma. In theory they may also be of benefit in bronchiectasis, but no randomised controlled trials have yet been reported so it is not possible to make a recommendation about their use in this condition.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2010 Issue 1, Copyright © 2010 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
October 23. 2000 AbstractBackgroundLeukotriene receptor antagonists are a new class of drug that were initially identified for use in asthma. As they have an effect on neutrophil mediated inflammation, they may be of benefit in bronchiectasis. ObjectivesTo determine whether leukotriene receptor antagonists have any additive benefit over and above conventional treatment for bronchiectasis (usually consisting of antibiotics and postural drainage). Search strategyThe Cochrane Airways Group Specialised Regsiter of trials and CENTRAL were searched up to April 2009. Selection criteriaOnly randomised, controlled trials were considered Data collection and analysisThe results of searches were analysed by both authors Main resultsNo randomised, controlled trials were identified. An update search conducted in April 2005 did not yield any further studies. Authors' conclusionsFurther research is required to establish any benefit from the use of leukotriene antagonists in bronchiectasis. |